March 7, 2025 – Cambridge, MA – Nona Biosciences has announced the launch of Hu-mAtrIx™, an advanced AI-driven antibody discovery platform designed to accelerate drug development. This cutting-edge technology integrates seamlessly with Harbour Mice®, the company’s proprietary fully human antibody platform, offering an efficient and precise approach to antibody discovery across therapeutic areas such as neurodegenerative and metabolic diseases.
Key Highlights of Hu-mAtrIx™
- Faster Drug Discovery: AI and automation reduce timelines and enhance efficiency.
- Smarter Antibody Selection: Scans vast libraries of human antibody sequences to identify optimal candidates with high specificity and binding affinity.
- Early Risk Mitigation: Predicts key antibody properties such as stability, manufacturability, and immunogenicity to minimize development risks.
Expanding Innovation with AI
In addition to Hu-mAtrIx™, Nona Biosciences is advancing its HCAb Plus™ platform by integrating AI technology with its HCAb Harbour Mice® system, a leading fully human heavy-chain-only transgenic mouse platform. This enhancement aims to push the boundaries of antibody discovery by identifying rare and highly specific antibodies with greater precision and efficiency.
A Transformative Approach to Drug Discovery
Dr. Jingsong Wang, Chairman of Nona Biosciences, emphasized the impact of AI in revolutionizing the drug discovery process: “By combining our proprietary Harbour Mice® with the power of AI, we are tackling key challenges in drug discovery—reducing time-to-market, improving success rates, and offering more targeted therapeutic solutions.”
About Nona Biosciences
Nona Biosciences is a global biotech company committed to innovation in antibody discovery and development. It offers a comprehensive solution from Idea to IND, leveraging advanced AI, single-cell screening, and next-generation sequencing to accelerate drug discovery.
Leave a Reply